During the past decade, Center for Neurosciences conducted 33 clinical trials. In the 10-year time frame, 33 clinical trials started and 16 clinical trials were completed, i.e. on average, 48.5% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 10 clinical trials were completed. i.e. 76.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Center for Neurosciences" #1 sponsor was "Eli Lilly and Company" with 9 trials, followed by "Biogen" with 3 trials sponsored, "Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc." with 3 trials sponsored, "Eisai Inc." with 2 trials sponsored and "Hoffmann-La Roche" with 2 trials sponsored. Other sponsors include 17 different institutions and companies that sponsored additional 23 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Center for Neurosciences" #1 collaborator was "Biogen" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator and "Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc." with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Center for Neurosciences" are "Alzheimer's Disease" (6 trials), "Alzheimer Disease" (3 trials), "Dravet Syndrome" (3 trials), "Glioblastoma Multiforme" (3 trials) and "Epilepsy, Partial Seizures" (2 trials). Many other conditions were trialed in "Center for Neurosciences" in a lesser frequency.

Most popular intervention types in "Center for Neurosciences" are "Drug" (35 trials), "Device" (5 trials), "Other" (2 trials), "Biological" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (16 trials), "ZX008 (Fenfluramine Hydrochloride)" (3 trials), "Aducanumab" (2 trials), "Bevacizumab" (2 trials) and "Donanemab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Center for Neurosciences" are 41 trials for "All" genders.

Currently, there are NaN active trials in "Center for Neurosciences". undefined are not yet recruiting, 9 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 20 completed trials in Center for Neurosciences, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Center for Neurosciences, 2 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 26 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 5 trials that are defined as “Not Applicable".